Y

Yeungnam University Medical Center | Department of Gastroenterology - Gastroenterology Laboratory Room

Research site
(Unclaimed)
Location
170 Hyeonchung-ro, Daegu, Daegu, South Korea
Site insights

Top conditions

Coronary Artery Disease (16 trials)

Colitis (14 trials)

Ulcer (14 trials)

Ulcerative Colitis (14 trials)

Crohn Disease (10 trials)

Top treatments

Risankizumab
Candesartan Cilexetil
Amlodipine Besylate
Vamikibart
Upadacitinib
ABT-494
Warfarin
Trastuzumab
Lazertinib
RO7200220

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

22 of 142
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2)

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two...

Enrolling
Type 2 Diabetes Mellitus
Drug: Cagrilintide
Drug: Semaglutide

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing g...

Enrolling
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Drug: Evorpacept (ALX148)
Drug: Trastuzumab

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting
Crohn Disease
Drug: Guselkumab Dose 2
Drug: Guselkumab Dose 1

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Other: Placebo
Drug: Guselkumab Dose 1

The study consists of 4 sub-studies, as follows:Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety...

Active, not recruiting
Crohn's Disease
Drug: Risankizumab SC
Drug: Risankizumab On-Body Injector (OBI)

Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokin...

Enrolling
Neovascular Age-related Macular Degeneration (nAMD)
Device: Port Delivery System with Ranibizumab
Drug: Ranibizumab

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: risankizumab
Drug: placebo for risankizumab

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Other: Sham Procedure
Drug: Faricimab

Study BP43464 is a phase II, multicenter, randomized, double-masked active comparator-controlled study designed to assess the efficacy, safety, toler...

Active, not recruiting
Diabetic Macular Edema
Drug: Vamikibart
Drug: Ranibizumab

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerabi...

Active, not recruiting
Diabetic Macular Edema
Drug: Ranibizumab
Drug: Vamikibart

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Enrolling
Uveitic Macular Edema
Drug: Vamikibart
Other: Sham

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Enrolling
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose
Diagnostic Test: Fluorescein

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of t...

Enrolling
Schizophrenia
Drug: Iclepertin

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients who have one of two t...

Enrolling
Marginal Zone Lymphoma (MZL)
Relapsed/Refractory Follicular Lymphoma
Drug: Rituximab
Drug: Lenalidomide

This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-s...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Gefitinib 250 mg
Drug: Gefitinib-matching placebo 250 mg

Antiphospholipid syndrome (APS) has a close association with ischemic stroke; however, the optimal treatment strategy for APS-related stroke has yet...

Enrolling
Ischemic Stroke
Antiphospholipid Syndrome
Drug: Warfarin
Drug: Antiplatelet Drug

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Example...

Enrolling
Schizophrenia
Drug: Placebo
Drug: iclepertin

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

Trial sponsors

AbbVie logo

AbbVie (12 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems